Latest News about Novo Nordisk A/S
Recent news which mentions Novo Nordisk A/S
From CNBC.com News
From CNBC.com News
Insurers face long road, high cost to cover obesity drugs after promising Wegovy heart health data
August 09, 2023
From CNBC.com News
Obesity drug Wegovy's landmark trial result could 'open up' health insurance access, analyst says
August 09, 2023
From CNBC.com News
Stocks making the biggest moves midday: Beyond Meat, Chegg, PNC Financial, Dish & more
August 08, 2023
From CNBC.com News
Stocks making the biggest moves premarket: UPS, Lucid, Beyond Meat, Novo Nordisk and more
August 08, 2023
From CNBC.com News
Eli Lilly says obesity drug helped boost weight loss to 26%, highest seen in late-stage trials
July 27, 2023
From CNBC.com News
From CNBC.com News
Weight loss drug Wegovy is from Europe — but users in the region face a long and costly wait
July 26, 2023
From CNBC.com News
From CNBC.com News
Uninsured Americans pay high costs for an insulin Eli Lilly vowed to price at $25, Sen. Warren says
July 13, 2023
From CNBC.com News
EU expands Wegovy, Ozempic probe over suicide risks to include other weight loss, diabetes drugs
July 11, 2023
From CNBC.com News
Few patients continue weight loss drugs like Wegovy after a year — but health costs soar for all
July 11, 2023
From CNBC.com News
From CNBC.com News
From CNBC.com News
Moderna strikes deal to develop mRNA drugs in China
July 05, 2023
From CNBC.com News
People should stop taking Ozempic, Wegovy obesity drugs before surgery, doctors group says
June 30, 2023
From CNBC.com News
As drugmakers race to develop the next big weight loss pill, Eli Lilly may have an edge
June 28, 2023
From CNBC.com News
Eli Lilly experimental obesity drug helped patients lose up to 24% of their weight, study says
June 26, 2023
From CNBC.com News
From CNBC.com News
From CNBC.com News
From CNBC.com News
Pfizer oral weight loss drug may be as effective as, quicker than Ozempic injection by Novo Nordisk, study says
May 22, 2023
From CNBC.com News
Eli Lilly CEO vows not to raise insulin prices again, while Novo Nordisk and Sanofi hedge
May 10, 2023
From CNBC.com News
From CNBC.com News
Obesity drug industry could be worth $200 billion within the decade, says Barclays, as market valuations grow
April 28, 2023
From CNBC.com News
From CNBC.com News
Eli Lilly, Novo Nordisk and Sanofi CEOs to testify before Senate on lowering insulin prices
April 21, 2023
From CNBC.com News
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.